A closing highlight of the programme is the joint symposium for all European Amgen Scholars in Cambridge, UK. In addition to conducting hands-on research, you will attend workshops and events offering ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Between 3% and 5% of colorectal cancers exhibit the KRAS G12C mutation. Credit: SewCreamStudio/Shutterstock. Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab ...

The Food and Drug Administration has approved Amgen sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...

The U.S. Food and Drug Administration (FDA) gave Amgen (NASDAQ:AMGN) approval to use its KRASG12C inhibitor Lumakras with Vectibix for treating advanced colorectal cancer. Warning! GuruFocus has ...

Jan 16 (Reuters) - The U.S. Food and Drug Administration approved Amgen's (AMGN.O), opens new tab combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.

The FDA on Thursday agreed to expand the label of Amgen’s KRAS inhibitor Lumakras (sotorasib), opening up its use in colorectal cancer. With the latest approval, Lumakras can now be combined with ...